A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations

Inclusion Criteria: * Healthy, adult, male or female * Body mass index ≥ 18.0 and ≤ 32.0 kg/m2 at screening * Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the Investigator * Have a Fitzpatrick skin type of I, II or III or have skin colorimeter scores equivalent to the allowed Fitzpatrick skin type Key Exclusion Criteria: * History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds (including piperidine derivatives and other cholinesterase inhibitors) * Has intolerance to venipuncture and/or inability to comply with the extensive blood sampling required for this study or does not have suitable veins in both arms * Potential for occupational exposure to anticholinesterase agents * Estimated creatinine clearance in non-elderly subjects \<80 mL/min at screening and in elderly subjects (i.e., ≥55 years of age) \<60 mL/min at screening * Hemoglobin value of less than 11.5 g/dl for females, 13.0 g/dl for males at screening and first check-in * Muscle relaxants, anti-Parkinsonian or neuroleptic medications prior to the first dose of study drug * History or presence of significant skin damage or other skin disturbances as deemed by the Investigator to potentially interfere with patch procedures * Use of donepezil hydrochloride or related drugs within 60 days prior to the first study drug administration * Clinically significant depression symptoms or suicidal ideation or behavior as determined by the Investigator